Business
Grant of Share Options
Trellus Health plc has issued 19,230,769 new Ordinary Shares in lieu of cash settlement for Secured Convertible Loan Notes, with admission to trading on AIM expected around February 2, 2026. Following this, the company will have a total of 180,739,102 Ordinary Shares in issue, each carrying one vote, and no shares held in treasury. This issuance is a result of resolutions passed at a General Meeting on January 20, 2026, following a prior announcement on December 30, 2025. Disclaimer*
About this update from Trellus Health Plc
[{"type":"text","content":"\n\nTrellus Health plc\n(\"Trellus Health\", the \"Company\" or the \"Group\")\n \nGrant of Share Options\n \nLONDON, U.K. AND NEW YORK, U.S. (29 January 2026). Trellus Health® plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces that further to the Company's announcement on 30 December 2025 and the passing of the relevant resolutions at the General Meeting on 20 January 2026, the Company has issued 19,230,769 new Ordinary Shares in lieu of cash payment of settlement fees relating to the Secured Convertible Loan Notes.\n \nAccordingly, application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 19,230,769 new Ordinary Shares to trading on AIM will become effective on, or around, 2 February 2026 (\"Admission\").\n \nTotal voting rights\nFollowing Admission, the Company will have 180,739,102 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 180,739,102.\n \nCapitalised terms used but not otherwise defined in this announcement shall have the meanings given to them in the Company's announcement released on 30 December 2025.\n \nFor further information please contact:\n \n\n\n\n\nTrellus Health plc\n\n\nhttps://trellushealth.com/\n\n\n\n\nDr. Marla Dubinsky, Chief Executive Officer and Co-Founder\n\n\nVia Walbrook PR\n\n\n\n\nJoy Bessenger, Chief Financial Officer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSinger Capital Markets (Nominated Adviser and Broker)\n\n\nTel: +44 (0)20 7496 3000\n\n\n\n\nPhilip Davies / James Todd / Patrick Weaver\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Lianne Applegarth /\nAlice Woodings\n\n\nMob: +44 (0)7980 541 893 / +44 (0)7584 391 303/\n+44 (0)7407 804 654\n\n\n\n\n\n\n\n\n\n \n \nAbout Trellus Health plc (www.trellushealth.com)\nTrellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services,...